Stock listing

NASDAQ:TPST Tempest Therapeutics, Inc. Stock

Home listing (NASDAQ) of Tempest Therapeutics, Inc.

Follow Tempest Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TPST

$0.287 USD -0.022 (-7.2%)

Close on Nov 20, 2026

Past year -92.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.280 – $0.297 USDNov 20, 2026
Volume
145,309 sharesNov 20, 2026
Market cap
$5.74M USDAt the close on Nov 20, 2026 · price × 20.00M shares outstanding
52-week range
$0.280 – $4.220 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.67M USDMedian day 177,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tempest Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TPST · Home$0.287 USD-0.022 (-7.2%)145,309$0.297$0.297$0.280$0.309Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TPST · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.287-0.022-7.2%$0.297$0.297$0.280145,309
$0.309-0.018-5.5%$0.326$0.350$0.301194,943
$0.327-0.015-4.2%$0.342$0.342$0.301180,785
$0.342-0.040-10.5%$0.381$0.389$0.34299,827
$0.382-0.001-0.3%$0.383$0.390$0.364150,065
$0.383-0.014-3.5%$0.379$0.400$0.370125,013
$0.397+0.023+6.1%$0.428$0.477$0.3791,467,834
$0.374+0.013+3.5%$0.397$0.400$0.337295,015
$0.361-0.019-5.0%$0.390$0.408$0.361227,677
$0.381+0.005+1.4%$0.410$0.410$0.38077,342
$0.375-0.088-19.0%$0.479$0.480$0.371308,095
$0.463-0.005-1.1%$0.462$0.500$0.45597,574
$0.469-0.003-0.7%$0.497$0.500$0.464140,361
$0.472-0.024-4.7%$0.500$0.505$0.470160,429
$0.496-0.038-7.1%$0.533$0.547$0.490140,906
$0.533-0.007-1.2%$0.549$0.560$0.53053,572
$0.540+0.029+5.7%$0.510$0.540$0.510100,043
$0.511+0.001+0.1%$0.520$0.531$0.51171,636
$0.510-0.001-0.2%$0.508$0.521$0.50165,901
$0.511-0.011-2.1%$0.534$0.542$0.50452,200
$0.522-0.006-1.1%$0.516$0.550$0.516188,500
$0.528-0.048-8.3%$0.570$0.623$0.520368,300
$0.576-0.024-4.0%$0.600$0.628$0.573138,300
$0.600-0.024-3.8%$0.640$0.640$0.600127,400
$0.624-0.011-1.7%$0.668$0.669$0.62067,100
$0.6350.0000.0%$0.633$0.653$0.620120,800
$0.635-0.046-6.8%$0.696$0.696$0.635179,100
$0.681-0.062-8.3%$0.747$0.747$0.680228,700
$0.743-0.017-2.2%$0.763$0.778$0.740163,600
$0.760-0.010-1.3%$0.776$0.810$0.760180,100
$0.770-0.021-2.7%$0.786$0.795$0.765147,100
$0.791+0.003+0.4%$0.790$0.820$0.750307,400
$0.788-0.005-0.6%$0.786$0.800$0.770217,600
$0.793-0.018-2.2%$0.800$0.825$0.782155,200
$0.811+0.005+0.6%$0.824$0.850$0.7802,271,700
$0.806-0.028-3.4%$0.810$0.830$0.800153,400
$0.834+0.024+3.0%$0.805$0.840$0.800265,000
$0.810-0.022-2.6%$0.826$0.851$0.804152,300
$0.832+0.003+0.4%$0.825$0.849$0.800256,400
$0.829-0.021-2.5%$0.868$0.895$0.815285,800
$0.850-0.072-7.8%$0.901$0.919$0.850442,400
$0.922-0.078-7.8%$0.989$1.010$0.899787,200
$1.000+0.226+29.2%$0.780$1.090$0.7703,611,100
$0.774-0.194-20.0%$0.920$0.945$0.7651,899,900
$0.968+0.073+8.2%$0.840$1.090$0.8404,799,000
$0.895-0.315-26.0%$1.080$1.080$0.8507,869,100
$1.210+0.455+60.3%$1.070$1.480$0.967104,597,900
$0.755-0.029-3.7%$0.799$0.809$0.74326,443,400
$0.784-0.028-3.4%$0.800$0.822$0.752138,700
$0.812+0.009+1.1%$0.790$0.887$0.758783,600
$0.803-0.106-11.7%$0.950$0.950$0.800391,000
$0.909-0.078-7.9%$0.985$0.990$0.909186,000
$0.987-0.043-4.2%$1.020$1.030$0.976199,600
$1.030-0.020-1.9%$1.040$1.050$1.010214,600
$1.050-0.050-4.5%$1.100$1.100$1.040181,900
$1.100+0.050+4.8%$1.050$1.120$1.050126,500
$1.050-0.040-3.7%$1.070$1.080$1.031177,300
$1.090+0.030+2.8%$1.060$1.130$1.06058,900
$1.060-0.020-1.9%$1.092$1.100$1.04062,300
$1.0800.0000.0%$1.100$1.110$1.07569,400
$1.080-0.030-2.7%$1.109$1.110$1.07051,700
$1.110+0.010+0.9%$1.110$1.130$1.08075,800
$1.100+0.060+5.8%$1.050$1.140$1.010198,800
$1.040+0.020+2.0%$1.020$1.080$1.000130,300
$1.020-0.050-4.7%$1.050$1.075$1.00589,500

Splits

3 splits since 2018 · NASDAQ:TPST · every price before a split is adjusted for it

DayRatioWhat
1-for-13Consolidation
1-for-15Consolidation
1-for-15Consolidation
Ticker
NASDAQ:TPST
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tempest Therapeutics, Inc. news

Tempest Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 90 in all · newest Nov 13, 2026 · oldest 2021
Decks
13 decks · latest Sep 15, 2026

Where Tempest Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TPST · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TPSTBOATSUnited StatesUSD
gettex:3OS0gettexGermanyEUR
Frankfurt:3OS0FrankfurtGermanyEUR
Lang & Schwarz:A41556Lang & SchwarzGermanyEUR
LS Exchange:A41556LS ExchangeGermanyEUR
Munich:3OS0MunichGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.84M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.09

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tempest Therapeutics, Inc. · NASDAQ:TPSTUS$5.74MUS$4.84Mn/an/an/an/an/an/a1.09
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Marvel Biosciences Corp · TSXV:MRVLUS$5.91MUS$6.04Mn/an/an/an/an/an/a0.91
Exicure, Inc. · NASDAQ:XCURUS$5.89MUS$4.67Mn/an/an/a3.1×n/a0.0×0.49
Oncotelic Therapeutics Inc · OTC:OTLCUS$5.58MUS$5.52M0.0×n/an/a0.0×n/a0.0×0.07
Theriva Biologics, Inc. · AMEX:TOVXUS$5.51MUS$461,120n/an/an/a0.5×n/a0.3×2.65
Hemostemix Inc · TSXV:HEMUS$5.35MUS$7.70Mn/an/an/an/an/an/a0.47
Median of the othersUS$5.93MUS$4.90M0.0×191×1.3×0.0×0.63

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
7.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.85 · 1 analyst

Team and board

Officers

OfficerRole
Andrew FangHead of Business Development

Board

DirectorRole
John W. FrederickBoard Member
Nancy Freda-SmithBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−10.5%
Q2 2026Aug 13, 2026 · After close−13.3%
Q1 2026May 15, 2026−12.9%
Q4 2025Mar 30, 2026 · Before open−12.1%
Q3 2025Nov 5, 2025 · Before open+9.1%
Q2 2025Aug 11, 2025 · After close+10.0%
Q1 2025May 13, 2025 · After close−3.5%
Q4 2024Mar 17, 2025 · Before open+1.8%
Q3 2024Nov 12, 2024 · After close−10.5%
Q2 2024Aug 8, 2024 · After close−14.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−6.3%
Q4 2023Mar 19, 2024 · After close+0.5%
Q3 2023Nov 8, 2023 · After close+16.3%
Q2 2023Aug 10, 2023 · After close+1.6%
Q1 2023May 10, 2023 · After close+2.9%
Q4 2022Mar 22, 2023 · After close+6.5%
Q3 2022Nov 8, 2022 · Before open−12.1%
Q2 2022Aug 15, 2022 · Before open+15.8%
Q1 2022May 13, 2022 · Before open+5.9%
Q4 2021Mar 29, 2022 · After close−7.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck11 slidesSep 15, 2026
Investor Presentation (May 2026)Investor deck23 slidesMay 6, 2026
Investor Presentation (February 2026)Investor deck40 slidesFeb 11, 2026
Technical Presentation (June 2022)Technical17 slidesJune 2022
Millendo Therapeutics — Merger or Acquisition (March 2021)Merger or acquisition23 slidesMar 29, 2021
Millendo Therapeutics — Investor Presentation (June 2020)Investor deck15 slidesJun 23, 2020
Millendo Therapeutics — Corporate Update (April 2020)Corporate update8 slidesApr 6, 2020
Millendo Therapeutics — Investor Presentation (January 2020)Investor deck24 slidesJan 13, 2020
Millendo Therapeutics — Investor Presentation (March 2019)Investor deck25 slidesMar 22, 2019
Millendo Therapeutics — Investor Presentation (January 2019)Investor deck25 slidesJan 7, 2019
All 13 decks
DeckKindSlidesDate
Technical Presentation (2019)Technical24 slides2019
OvaScience — Merger or Acquisition (August 2018)Merger or acquisition20 slidesAug 9, 2018
OvaScience — Investor Presentation (January 2018)Investor deck30 slidesJan 8, 2018

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants
Announced: about US$2.5M · US$0.805 a share · Warrants at US$0.805 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Sep 11, 2026
Strategic investment of investment commitment
Update: strategic investment
Buyers: Factor Bioscience Inc. (investment commitment / financing support)
Use of proceeds: Together with existing cash, expected to provide a runway to mid-2027 and potentially through key data milestones
Feb 4, 2026
Registered direct offering of shares of common stock (or common stock equivalents) with concurrent private placement of short-term unregistered warran
Closed: US$4.25M raised · US$3.625 a share · Warrants at US$3.5 for 18 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Primarily working capital and general corporate purposes
Nov 26, 2025
Registered direct offering of shares of common stock (or common stock equivalents)
Announced: about US$4.6M · US$6.25 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: single institutional investor (739,000 shares of common stock (or common stock equivalents))
Use of proceeds: Supporting the previously announced strategic alternative process, working capital and general corporate purposes
Jun 11, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000295.0K653.0K
Cost of revenue389.0K381.0K1.81M1.27M815.0K1.05M32.0K790.0K5.40M
Gross profit-389.0K-381.0K-1.81M-1.27M-815.0K-1.05M-32.0K267.0K-4.75M
Research and development12.6M28.5M17.5M22.5M17.2M14.4M27.8M14.4M18.3M21.6M
Selling, general and administrative14.0M13.6M11.7M12.1M9.82M4.91M17.6M8.69M27.7M49.2M
Operating income-26.6M-42.0M-29.2M-34.6M-27.0M-19.3M-45.4M-26.9M-84.3M-81.0M
Depreciation and amortization266.0K389.0K381.0K638.0K374.0K339.0K97.0K32.0K1.65M2.24M
EBITDA-26.3M-41.6M-28.8M-34.0M-26.6M-19.0M-45.3M-26.8M-82.7M-78.8M
Interest expense207.0K1.32M1.45M1.62M1.28M01.04M134.0K288.0K659.0K
Income before tax-26.3M-41.8M-29.5M-35.7M-28.3M-19.2M-44.6M-27.2M-50.9M-82.1M
Income tax0000001.00K-169.0K67.0K201.0K
Net income-26.3M-41.8M-29.5M-35.7M-28.3M-19.2M-44.6M-27.2M-84.6M-82.3M
Earnings per share, basic-6.33-19.50-1.91-3.09-7.47-41.03-3.25-17.58-321.81-2.56
Earnings per share, diluted-6.33-19.50-1.91-3.09-7.47-41.03-3.25-17.58-321.81-2.56

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.71M30.3M39.2M31.2M51.8M18.8M62.5M73.3M17.6M43.9M
Short-term investments051.5M70.5M
Receivables450.0K15.0M260.0K1.28M2.33M1.03M
Inventory1.58M686.0K1
Current assets8.27M31.5M40.4M33.0M69.0M19.8M71.1M83.4M19.7M116.4M
Property, plant and equipment605.0K886.0K840.0K1.06M1.11M1.11M3.75M3.11M5.57M
Total assets16.9M41.5M51.6M46.1M73.2M22.9M75.0M84.1M19.8M122.5M
Accounts payable1.04M2.45M845.0K1.11M991.0K1.07M1.50M2.00M1.30M2.18M
Current liabilities3.31M14.2M9.41M7.28M20.0M3.22M12.5M9.82M4.09M13.2M
Long-term debt06.26M10.4M15.1M0168.0K383.0K599.0K
Total debt06.40M10.5M10.4M15.1M239.0K376.0K572.0K599.0K
Total liabilities10.3M22.4M24.8M28.0M37.1M4.95M15.1M11.0M4.83M14.3M
Shareholders' equity6.67M19.1M26.8M18.1M36.1M-68.8M-50.4M71.0M-130.7M108.2M
Shares outstanding4.93M3.38M22.0M10.5M6.91M527.3K18.3M13.4M246.3K35.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-26.8M-33.0M-27.4M-31.1M-26.0M-19.0M-41.2M-23.6M-20.3M-61.7M
Capital spending0-435.0K-170.0K-562.0K-135.0K-50.0K-397.0K-36.0K-4.00K-2.59M
Free cash flow-26.8M-33.5M-27.5M-31.6M-26.1M-19.1M-41.6M-23.7M-20.3M-64.3M
Cash from investing0-435.0K-170.0K-562.0K-97.0K-6.00K3.99M1.93M458.0K8.29M
Cash from financing4.26M24.5M35.6M11.4M59.1M34.6M26.9M77.7M-4.46M54.1M
Change in cash-22.6M-8.96M8.07M-20.2M33.0M-24.9M-10.3M56.1M-24.3M706.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
DEFA14A · Additional proxy materialNov 16, 2026Meeting noticeSEC
8-K · Current reportNov 16, 2026Meeting outcomeSEC
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026Current reportSEC
8-K · Current reportNov 10, 2026Meeting outcomeSEC
8-K · Current reportNov 5, 2026Current reportSEC
3 · Initial statement of ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipNov 2, 2026Insider tradeSEC
ARS · Annual report to shareholdersNov 2, 2026Annual reportSEC
8-K · Current reportOct 30, 2026Management or board changeSEC
DEF 14A · Proxy statementOct 26, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialOct 20, 2026Meeting noticeSEC
8-K · Current reportOct 20, 2026Meeting outcomeSEC
8-K · Current reportOct 19, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementOct 16, 2026Meeting noticeSEC
DOct 13, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2026Insider tradeSEC
424B3 · ProspectusOct 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 2, 2026Other filingsSEC
8-K · Current reportSep 28, 2026Material contractSEC
S-3 · Registration statementSep 25, 2026Offer documentSEC
8-K · Current reportSep 17, 2026Material contractSEC
DEFA14A · Additional proxy materialSep 16, 2026Meeting noticeSEC
8-K · Current reportSep 16, 2026Meeting outcomeSEC
8-K · Current reportSep 15, 2026Material contractSEC
424B3 · ProspectusSep 1, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 1, 2026Other filingsSEC
CORRESP · Letter to the SECAug 27, 2026Other filingsSEC
UPLOAD · Letter from the SECAug 27, 2026Other filingsSEC
8-K · Current reportAug 24, 2026Management or board changeSEC
S-1 · Registration statementAug 21, 2026Offer documentSEC
DEFA14A · Additional proxy materialAug 18, 2026Meeting noticeSEC
8-K · Current reportAug 18, 2026Meeting outcomeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
8-K · Current reportAug 13, 2026Material contractSEC
DEFA14A · Additional proxy materialJul 28, 2026Meeting noticeSEC
8-K · Current reportJul 28, 2026Meeting outcomeSEC
8-K · Current reportJul 22, 2026Material contractSEC
DEF 14A · Proxy statementJul 17, 2026Meeting noticeSEC
424B3 · ProspectusJul 8, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 8, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementJul 7, 2026Meeting noticeSEC
CORRESP · Letter to the SECJul 2, 2026Other filingsSEC
UPLOAD · Letter from the SECJul 2, 2026Other filingsSEC
S-3 · Registration statementJun 26, 2026Offer documentSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
DJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
DEF 14A · Proxy statementJun 8, 2026Meeting noticeSEC
8-K · Current reportJun 4, 2026Management or board changeSEC
8-K · Current reportJun 1, 2026Material contractSEC
PRE 14A · Preliminary proxy statementMay 29, 2026Meeting noticeSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
8-K · Current reportMay 22, 2026Current reportSEC
8-K · Current reportMay 22, 2026Management or board changeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 6, 2026Current reportSEC
424B3 · ProspectusApr 10, 2026Offer documentSEC
424B3 · ProspectusApr 10, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 10, 2026Other filingsSEC
CORRESP · Letter to the SECApr 8, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
DApr 3, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
S-3 · Registration statementApr 1, 2026Offer documentSEC
CORRESP · Letter to the SECApr 1, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2026Other filingsSEC
S-8 POSMar 31, 2026Offer documentSEC
S-3 · Registration statementMar 30, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 25, 2026Big-stake noticeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
8-K · Current reportMar 23, 2026Material contractSEC
8-K · Current reportFeb 25, 2026Current reportSEC
8-K · Current reportFeb 11, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeFeb 10, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 6, 2026Insider tradeSEC
8-K · Current reportFeb 6, 2026Acquisition or disposalSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 9, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 2, 2026Other filingsSEC
ARS · Annual report to shareholdersDec 31, 2025Annual reportSEC
DEF 14A · Proxy statementDec 31, 2025Meeting noticeSEC
CORRESP · Letter to the SECDec 30, 2025Other filingsSEC
CORRESP · Letter to the SECDec 23, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 12, 2025Other filingsSEC
S-1 · Registration statementDec 9, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementDec 2, 2025Meeting noticeSEC
8-K · Current reportNov 26, 2025FinancingSEC
424B5 · ProspectusNov 25, 2025Offer documentSEC
DEFA14A · Additional proxy materialNov 19, 2025Meeting noticeSEC
8-K · Current reportNov 19, 2025Material contractSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportJun 12, 2025Material contractSEC
424B5 · ProspectusJun 12, 2025Offer documentSEC
8-K · Current reportJun 11, 2025Current reportSEC
8-K · Current reportJun 6, 2025Management or board changeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
8-K · Current reportApr 28, 2025Current reportSEC
8-K · Current reportApr 18, 2025Current reportSEC
8-K · Current reportApr 9, 2025Current reportSEC
8-K · Current reportApr 7, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
424B5 · ProspectusFeb 6, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 28, 2025Other filingsSEC
CORRESP · Letter to the SECJan 24, 2025Other filingsSEC
S-3/A · Registration statement, amendedJan 24, 2025Offer documentSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
8-K · Current reportDec 31, 2024Current reportSEC
8-K · Current reportDec 6, 2024Material contractSEC
DEF 14A · Proxy statementNov 12, 2024Meeting noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
PRE 14A · Preliminary proxy statementOct 29, 2024Meeting noticeSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedOct 10, 2024Other filingsSEC
8-K · Current reportOct 10, 2024Material contractSEC
144 · Notice of proposed saleAug 13, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedAug 12, 2024Big-stake noticeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
144 · Notice of proposed saleAug 9, 2024Other filingsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
UPLOAD · Letter from the SECJul 23, 2024Other filingsSEC
S-3 · Registration statementJul 19, 2024Offer documentSEC
4 · Change in ownershipJul 8, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
424B5 · ProspectusJun 20, 2024Offer documentSEC
8-K · Current reportJun 20, 2024Material contractSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedMay 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansMar 19, 2024Offer documentSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 8, 2024Big-stake noticeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
S-8 POSNov 17, 2023Offer documentSEC
S-8 POSNov 17, 2023Offer documentSEC
S-8 POSNov 17, 2023Offer documentSEC
S-8 POSNov 17, 2023Offer documentSEC
S-8 POSNov 17, 2023Offer documentSEC
S-8 · Registration statement for employee plansNov 17, 2023Offer documentSEC
SC 13D/A · Big-stake notice, amendedNov 9, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
144 · Notice of proposed saleNov 2, 2023Other filingsSEC
8-K · Current reportOct 30, 2023Current reportSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
424B5 · ProspectusOct 12, 2023Offer documentSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tempest Therapeutics, Inc.’s releases · as of Nov 13, 2026

Common shares
19,995,358
Fully diluted
19,995,358

Fully diluted

LineSharesAs of
Common shares19,995,358Nov 13, 2026

Warrants and options

Lot
Warrants · US$3.50 · expire about May 2027

Share count over time

CountShares
Nov 13, 202619,995,358

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard314K1.6%US$262KSep 30, 2026
Geode Capital74,0760.37%US$61,802Sep 30, 2026
BlackRock39,0680.20%US$32,594Sep 30, 2026
UBS25,1700.13%US$20,991Sep 30, 2026
Hrt Financial LP21,3150.11%US$17,000Sep 30, 2026
Northern Trust20,1360.10%US$16,799Sep 30, 2026
Citigroup Inc15,4260.08%US$12,870Sep 30, 2026
StoneX Group Inc.13,6680.07%US$11,653Sep 30, 2026
TRB Wealth Management, LLC10,8460.05%US$9,049Sep 30, 2026
Nuveen5,9580.03%US$4,828Sep 30, 2026
All 21 holders
HolderSharesOf the companyValueAs of
Tower Research Capital LLC (TRC)4,8460.02%US$4,043Sep 30, 2026
Morgan Stanley2,0220.01%US$1,687Sep 30, 2026
Osaic Holdings, Inc.1,439<0.01%US$1,156Sep 30, 2026
Federation des caisses Desjardins du Quebec292<0.01%US$244Sep 30, 2026
Northwestern Mutual Wealth Management Co134<0.01%US$112Sep 30, 2026
SBI Securities Co., Ltd.56<0.01%US$47Sep 30, 2026
RBC28<0.01%Sep 30, 2026
Parallel Advisors, LLC18<0.01%US$15Sep 30, 2026
Fidelity15<0.01%US$13Sep 30, 2026
BNP Paribas3<0.01%US$2Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund129K0.64%US$143KJun 30, 2026
Vanguard Total Stock Market Index Fund105K0.52%US$116KJun 30, 2026
Fidelity Extended Market Index Fund50,9850.25%US$78,007May 31, 2026
Fidelity Series Total Market Index Fund15,6770.08%US$23,986May 31, 2026
Fidelity Total Market Index Fund7,4950.04%US$11,467May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Angel Matthew
Director, Officer: CEO and President, 10% owner
Buy231,482USD 2.16US$500KMar 24, 2026

Big stakes

StakeStakeSharesDateFiling
Matthew Angel37.40%5.53MMar 24, 2026Schedule 13D
Sabby Management, LLC9.90%492KDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carol G. Gallagher
Other companies: TRex Bio, Inc. (Lead Independent Director · Since at least Nov 5, 2026); PMV Pharmaceuticals, Inc. (Director · Since at least Nov 3, 2022); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past)
Director · Jun 20, 2019 – Jun 22, 2020 · Past
Mary Lynne Hedley
Other companies: Eli Lilly and Company (Director · Since at least May 15, 2022); Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); Veeva Systems Inc. (Director · Since at least Aug 16, 2019); Bluebird bio Inc (Director · Sep 18, 2017 – Jun 20, 2018 · Past); Receptos Inc (Director · Apr 11, 2014 – Aug 27, 2015 · Past); Tesaro Inc (President & COO, Director · Jun 27, 2012 – Jan 22, 2019 · Past); Abraxis BioScience Inc (Executive VP of Ops & CSO · Jul 9, 2009 – Jul 13, 2009 · Past)
Director · Dec 7, 2018 – Jun 22, 2020 · Past
Arthur Tzianabos
Other companies: Stoke Therapeutics, Inc. (Chairman · Since at least Jun 18, 2019); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); BIND Therapeutics Inc (Director · Oct 9, 2015 – Jun 21, 2016 · Past)
President and CSO · Sep 3, 2013 – Dec 3, 2015 · Past
Richard Aldrich
Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 3, 2018 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); PTC Therapeutics, Inc. (Director · Mar 7, 2013 – Jun 8, 2015 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past)
Director · Jun 11, 2012 – Dec 7, 2018 · Past
Tamara L Joseph
Other companies: Spero Therapeutics, Inc. (Chief Legal Officer · Dec 2, 2020 – Feb 1, 2024 · Past); InVivo Therapeutics Holdings Corp (SVP, General Counsel · Mar 24, 2014 – Jan 18, 2017 · Past); Cubist Pharmaceuticals Inc (SVP, GC & Secretary · Apr 30, 2008 – Jun 29, 2012 · Past)
General Counsel and Secretary · Aug 19, 2019 – May 25, 2020 · Past
David Harding
Other companies: T2 Biosystems, Inc. (Chief Commercial Officer · Oct 30, 2015 – Feb 9, 2017 · Past); Hologic Inc (Group VP & GM, Women's Health · Jun 28, 2013 – Nov 18, 2013 · Past)
Chief Commercial Officer · Apr 10, 2014 – Dec 9, 2014 · Past
Jeffrey E Young
Other companies: Harvard Apparatus Regenerative Technology Inc (Director · Nov 6, 2018 – Jun 25, 2020 · Past); Juniper Pharmaceuticals Inc (Chief Financial Officer · Jan 1, 2017 – Aug 14, 2018 · Past)
Chief Financial Officer · Sep 8, 2014 – Dec 3, 2015 · Past
Michael Raab
Other companies: Ardelyx, Inc. (President & CEO, Director · Since at least Jan 19, 2017); Amicus Therapeutics Inc (Director · Since at least Jun 9, 2016)
Director · Since at least Jun 25, 2021
Thomas Malley
Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Kura Oncology, Inc. (Director · Since at least Oct 13, 2015)
Director · Jun 30, 2015 – Jun 13, 2017 · Past
Christophe Couturier
Other companies: Avantor, Inc. (EVP, AMEA · Since at least May 16, 2019)
Chief Financial Officer · Sep 6, 2016 – Mar 2, 2017 · Past
All 28 people
PersonSeat
John Yee
Other companies: Apnimed, Inc. (Senior Vice President, Medical Affairs · Since at least Nov 5, 2026)
Director · Since at least Jun 4, 2026
Julia C Owens
Other companies: Metacrine Inc (Director · Apr 1, 2021 – May 18, 2022 · Past)
Executive Chair, Director · Dec 7, 2018 – Mar 17, 2021 · Past
Louis J Arcudi III
Other companies: Aceragen Inc. (Chief Financial Officer · Jan 3, 2017 – Aug 13, 2018 · Past)
President and CEO, Director · Dec 7, 2018 – Feb 26, 2021 · Past
Matthew Angel
Other companies: Ernexa Therapeutics Inc. (President and CEO, Director · May 26, 2022 – Jan 12, 2023 · Past)
CEO and President, Director · Since at least Feb 3, 2026
Pharis Mohideen
Other companies: DBV Technologies SA (Chief Medical Officer · Since at least Jan 1, 2021)
Chief Medical Officer · Dec 7, 2018 – Jan 15, 2019 · Past
Randall W Whitcomb
Other companies: Insmed Incorporated (Director · Jan 10, 2014 – Mar 10, 2015 · Past)
Director · Dec 7, 2018 – Jun 20, 2019 · Past
Thomas W Dubensky
Other companies: Aduro Biotech Inc (Chief Scientific Officer · Apr 14, 2015 – Aug 10, 2017 · Past)
President, Director · Jun 25, 2021 – Jan 3, 2023 · Past
Andrew FangHead of Business Development · Since at least May 14, 2026
Geoffrey NicholDirector · Since at least Jun 13, 2024
Harald F StockDirector · Feb 8, 2013 – Jan 5, 2016 · Past
John W. FrederickBoard Member · Since at least Oct 14, 2026
Justin TrojanowskiCorporate Controller · Since at least Sep 30, 2022
Nancy Freda-SmithBoard Member · Since at least Sep 23, 2026
Ronit SimantovDirector · Since at least Jan 27, 2026
Samuel WhitingChief Medical Officer · Jun 25, 2021 – Jan 2, 2025 · Past
Sam WhitingChief Medical Officer · Aug 13, 2025 – Nov 4, 2026 · Past
Theresa McNeelyEVP, Chief Comm. Officer · Dec 9, 2014 – Apr 8, 2015 · Past
William Drake RicheyDirector · Since at least Jun 4, 2026

Open People

Log in to ask 6ix AI your own questions about Tempest Therapeutics, Inc.